Tag Archives: aggregate spend

As the perceived urgency for transparency and compliance in global pharma grows ever stronger, the ‘Sunshine provisions’ of the US’s Patient Protection and Affordable Care Act (ACA) seem increasingly aptly named. The spotlight that has been exposing and illuminating – and sometimes burning – issues around the financial interests of physicians and academic medical centers [...]